Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia among adults. Although chemoimmunotherapy prolongs the duration of remission and overall survival among most patients with CLL, relapse virtually always occurs. This has prompted aggressive discovery efforts for new therapies in CLL.…

from Medicine via xlomafota13 on Inoreader http://ift.tt/1OeSGqg
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IBh4Wx
via IFTTT